^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    zurletrectinib (ICP-723)

    i
    Other names: ICP-723
    Company:
    InnoCare
    Drug class:
    pan-TRK inhibitor
    Related drugs:
    6ms
    Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents. (PubMed, Br J Cancer)
    Our data identifies zurletrectinib as a novel, highly potent next-generation TRK inhibitor with stronger in vivo brain penetration and intracranial activity than other next-generation agents.
    Journal
    |
    NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    Vitrakvi (larotrectinib) • Augtyro (repotrectinib) • zurletrectinib (ICP-723) • selitrectinib (BAY 2731954)
    10ms
    A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=310, Recruiting, Beijing InnoCare Pharma Tech Co., Ltd. | N=42 --> 310
    Enrollment change
    |
    zurletrectinib (ICP-723)
    almost2years
    A Phase 2 Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors (clinicaltrials.gov)
    P1/2, N=55, Recruiting, Beijing InnoCare Pharma Tech Co., Ltd.
    New P1/2 trial • Metastases
    |
    NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK fusion
    |
    zurletrectinib (ICP-723)